Karina Nørgaard Linde

Karina Nørgaard Linde

Auto-generated profile, based on publicly available information

Karina Nørgaard Linde

Department of Orthopaedics, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2017 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
KLKarina Nørgaard Linde
Karina Nørgaard Linde
KPKatriina Bøcker Puhakka
Katriina Bøcker Puhakka
BLBente Lomholt Langdahl
Bente Lomholt Langdahl
KSKjeld Soballe
Kjeld Soballe
IKInger Krog-Mikkelsen
Inger Krog-Mikkelsen
Maiken StillingMaiken Stilling
Maiken Stilling

31 January 2022 in Knee Surgery, Sports Traumatology, Arthroscopy
Verified
Journal Article
Closed access
PDF file
KLKarina Nørgaard Linde
Karina Nørgaard Linde
SRSøren Rytter
Søren Rytter
KSKjeld Søballe
Kjeld Søballe
FMFrank Madsen
Frank Madsen
BLBente Langdahl
Bente Langdahl
MSMaiken Stilling
Maiken Stilling

1 August 2025 in The Bone & Joint Journal
Verified
Journal Article
Closed access
PDF file
KLKarina Nørgaard Linde
Karina Nørgaard Linde
SRSøren Rytter
Søren Rytter
BLBente Lomholt Langdahl
Bente Lomholt Langdahl
FMFrank Madsen
Frank Madsen
MSMaiken Stilling
Maiken Stilling
Aims: The aim of this study was to investigate if adjuvant treatment with antiresorptive bone medication improves fixation of cementless total knee arthroplasty. We hypothesized that local bisphosphonate (zoledronate) or systemic denosumab would both decrease implant migration.Methods: This four-way, double-blinded, randomized trial included 108 patients with primary knee osteoarthritis with a five-year follow-up. Three groups had the same cementless total knee tibial implant and were included in this primary study (n = 82). Patients were randomized to either placebo (n = 27), intraoperative local zoledronate (n = 28), or postoperative denosumab (n = 27). The primary outcome was tibial implant migration measured by radiostereometric analysis (RSA) using maximum total point motion (MTPM) and signed migrations. Secondary outcomes were biochemical bone markers (resorption: serum collagen type 1 cross-linked C-telopeptide (CTX); formation: serum type 1 procollagen N-terminal (P1NP)), periprosthetic bone mineral density (BMD), and patient-reported outcomes.Results: At one year, the mean difference in MTPM between zoledronate and placebo was 0.43 mm (95% CI 0.01 to 0.85; p = 0.043), and 0.42 mm (95% CI 0.00 to 0.83; p = 0.048) between denosumab and placebo. At five years, the intervention groups showed less y-translation (subsidence) than placebo: mean difference of 0.50 mm for zoledronate (95% CI 0.23 to 0.78; p < 0.001) and 0.30 mm for denosumab (95% CI 0.03 to 0.58; p = 0.031). CTX was lower in the zoledronate group than in the placebo group at two- and six-week follow-up. In the denosumab group, CTX was lower until one year postoperatively. P1NP were similar in the placebo and zoledronate groups, but lower in the denosumab group up to one year postoperatively. Periprosthetic BMD was higher in intervention groups, with a lasting effect in the zoledronate group at five years.Conclusion: Both interventions decreased cementless tibial implant migration by suppressing bone resorption. Local zoledronate had a lasting mitigating effect on subsidence and the periprosthetic BMD. Our findings support the use of local intraoperative zoledronate during knee arthroplasty surgery to improve cementless tibial implant fixation and preserve tibial bone. However, multicentre studies and prospective cohort quality studies should be performed for confirmation.Cite this article: Bone Joint J 2025;107-B(8):793–803.

7 July 2025 in Knee Surgery, Sports Traumatology, Arthroscopy
Verified
Journal Article
Open access
CBCarl Christian Holkgaard Burvil
Carl Christian Holkgaard Burvil
KLKarina Nørgaard Linde
Karina Nørgaard Linde
Maiken StillingMaiken Stilling
Maiken Stilling
THTorben Bæk Hansen
Torben Bæk Hansen
JDJesper Dalsgaard
Jesper Dalsgaard
EPEmil Toft Petersen
Emil Toft Petersen
Purpose: To assess the influence of a higher constraint medial congruent (MC) versus a cruciate retaining (CR) (gold standard) polyethylene insert on the migration of cemented tibial and femoral components of the Persona Total Knee System. High‐constraint inserts may increase forces on components and potentially affect implant migration and long‐term fixation. Methods: A cohort of 66 patients with primary knee osteoarthritis received a cemented Persona total knee arthroplasty and were randomised to either an MC or a CR polyethylene insert. Tibial and femoral component migration was assessed using static radiostereometric analysis, with the first stereo‐radiograph taken supine on the first postoperative day (baseline) and again at 3‐, 12‐, and 24‐month follow‐up. Tibial and femoral component migration was evaluated in six degrees of freedom and as maximum total point motion (MTPM). Results: At the 12‐month follow‐up, the mean difference in tibial component MTPM was 0.04 mm (95% confidence interval [CI]: −0.21 to 0.28). The mean MTPM was 0.81 mm (95% CI: 0.64–0.99) in the MC group and 0.85 mm (95% CI: 0.68–1.03) in the CR group. Signed migrations were similar for the MC and the CR group throughout 24 months of follow‐up ( p > 0.09). At the 12‐month follow‐up, the mean difference in femoral component MTPM was 0.18 mm (95% CI: −0.17 to 0.53). The mean MTPM was 1.08 mm (95% CI: 0.83–1.32) in the MC group and 1.26 mm (95% CI: 1.01–1.51) in the CR group. The femoral components with MC insert had 0.18 mm (95% CI: 0.03–0.32) and 0.20 mm (95% CI: 0.01–0.39) more lateral migration at 3‐ and 12‐month follow‐up, respectively. At the 24‐month follow‐up, there was no statistically significant differences in migration for either translations, rotations or MTPM. Conclusions: Both tibial and femoral components had similar and acceptable fixation regardless of the type of polyethylene insert. Level of Evidence: Level I.